Ortoma AB, a Swedish medical technology company, has announced that it has signed a development and distribution agreement with DePuy Ireland Unlimited Company (“DePuy Synthes”), part of Johnson & Johnson MedTech. The deal will allow Ortoma to integrate DePuy Synthes’ technology into its customized Ortoma Treatment Solution (OTS) for hip replacement surgery.
Linus Byström, CEO of Ortoma, stated, “Ortoma is moving step by step towards global establishment of OTS and through our strategic collaboration we will be able to reach important markets such as the US and Europe.”
The market launch of Custom OTS is expected to take place in 2024 with an initial focus on sales in the markets where regulatory clearances have been obtained.
Ortoma Treatment Solution (OTS™) is a product used for orthopedic procedures, specifically for hip surgery, that includes OTS™ Hip Plan and OTS™ Hip Guide for preoperative planning, intraoperative navigation, and postoperative follow-up of hip implant surgery. The system’s software, which is based on artificial intelligence, enables improved accuracy, efficiency, and surgical results.